-
1Academic Journal
Authors: S. Yu. Serebrova, V. V. Evteev, E. Yu. Demchenkova, M. V. Zhuravleva, A. B. Prokofiev, С. Ю. Сереброва, В. А. Евтеев, Е. Ю. Демченкова, М. В. Журавлева, А. Б. Прокофьев
Contributors: This study was conducted by the Scientific Centre for Expert Evaluation of Medicinal Products as part of the applied research funded under State Assignment No. 056-00026-24-01 (R&D Registry No. 124022200076-2), Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-01 на проведение прикладных научных исследований (номер государственного учета НИР № 124022200076-2)
Source: Safety and Risk of Pharmacotherapy; Том 12, № 4 (2024); 367-379 ; Безопасность и риск фармакотерапии; Том 12, № 4 (2024); 367-379 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-4
Subject Terms: сополимер метакриловой кислоты и метилметакрилата, mesalamine, 5-aminosalicylic acid, ulcerative colitis, Crohn’s disease, colon, inflammatory bowel disease, enteric coatings, enteric-coated dosage forms, methacrylic acid-methyl methacrylate copolymer, месаламин, 5-аминосалициловая кислота, язвенный колит, болезнь Крона, толстая кишка, воспалительные заболевания кишечника, кишечнорастворимые оболочки, кишечнорастворимые лекарственные формы
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/456/1275; https://www.risksafety.ru/jour/article/downloadSuppFile/456/553; https://www.risksafety.ru/jour/article/downloadSuppFile/456/570; https://www.risksafety.ru/jour/article/downloadSuppFile/456/572; https://www.risksafety.ru/jour/article/downloadSuppFile/456/580; https://www.risksafety.ru/jour/article/downloadSuppFile/456/581; https://www.risksafety.ru/jour/article/downloadSuppFile/456/582; https://www.risksafety.ru/jour/article/downloadSuppFile/456/586; GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. https://doi.org/10.1016/S2468-1253(19)30333-4; Iacucci M, de Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010;24(2):127–33. https://doi.org/10.1155/2010/586092; Ciorba MA. Inflammatory bowel diseases 2024. Curr Opin Gastroenterol. 2024;40(4):233–4. https://doi.org/10.1097/MOG.0000000000001038; Mukherji G, Wilson CG. Biopolymers and colonic delivery. In: Rathbone MJ, Hadgraft J, Roberts MS, eds. Modified-release drug delivery technology. New York: Marcel Dekker; 2003. P. 223–32.; Mohylyuk V, Yerkhova A, Katynska M, Sirko V, Patel K. Effect of elevated pH on the commercial enteric-coated omeprazole pellets resistance: patent review and multisource generics comparison. AAPS PharmSciTech 2021;22(5):188. https://doi.org/10.1208/s12249-021-02038-2; Little RD, Jayawardana T, Koentgen S, Zhang F, Connor SJ, Boussioutas A, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. Gastroenterology. 2024;2:e100006. https://doi.org/10.3390/diagnostics13172797; Fiocchi C, Dragoni G, Iliopoulos D, Katsanos K, Ramirez VH, Suzuki K. Results of the Seventh Scientific Workshop of ECCO: precision medicine in IBD—what, why, and how. J Crohns Colitis. 2021;15(9):1410–30. https://doi.org/10.1093/ecco-jcc/jjab051; Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand. 1942;110:577–98. https://doi.org/10.1111/j.0954-6820.1942.tb06841.x; Шапина МВ, Халиф ИЛ. Применение препаратов 5-аминосалициловой кислоты для лечения язвенного колита в различных режимах дозирования. Медицинский совет. 2017;(15):44–50. https://doi.org/10.21518/2079-701X-2017-15-44-50; Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P, Clementi E. Five-aminosalicylic acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract. 2015;2015:456895. https://doi.org/10.1155/2015/456895; Сереброва СЮ, Евтеев ВА, Демченкова ЕЮ, Прокофьев АБ. Компендиум рН-чувствительных полимеров в лекарственных препаратах, применяемых в гастроэнтерологии: фокус на кишечнорастворимые оболочки. Медицинский совет. 2024;(5):134–42. https://doi.org/10.21518/ms2024-039; Sester C, Ofridam F, Lebaz N, Gagnière E, Mangin D, Elaissari A. pH-sensitive methacrylic acid–methyl methacrylate copolymer Eudragit L100 and dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate tri-copolymer Eudragit E100. Polym Adv Technol. 2019;31:440–50. https://doi.org/10.1002/pat.4780; Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, et. al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002;231(1):83–95. https://doi.org/10.1016/S0378-5173(01)00871-7; Foppoli A, Maroni A, Moutaharrik S, Melocchi A, Zema L, Palugan L, et al. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. Int J Pharm. 2019;572:118723. https://doi.org/10.1016/j.ijpharm.2019.118723; Ibekwe VC, Khela MK, Evans DF, Basit AW. A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology. Aliment Pharmacol Ther. 2008;28(7):911–6. https://doi.org/10.1111/j.1365-2036.2008.03810.x; Varum F, Freire AC, Bravo R, Basit AW. OPTICORE™, an innovative and accurate colonic targeting technology. Int J Pharm. 2020;583:119372. https://doi.org/10.1016/j.ijpharm.2020.119372; Preisig D, Varum F, Bravo R, Hartig C, Spleiss J, Abbes S, et al. Colonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: a clinical pharmacoscintigraphy study. Eur J Pharm Biopharm. 2021;165:22–30. https://doi.org/10.1016/j.ejpb.2021.05.002; Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2024;18(10):1531–55. https://doi.org/10.1093/ecco-jcc/jjae091; Silverberg M, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36. https://doi.org/10.1155/2005/269076; Wahlgren M, Axenstrand M, Hakansson A, Marefati A, Pedersen LB. In vitro methods to study colon release: state of the art and an outlook on new strategies for better in-vitro biorelevant release media. Pharmaceutics. 2019;11(2):95. https://doi.org/10.3390/pharmaceutics11020095; Yamamura R, Inoue KY, Nishino K, Yamasaki S. Intestinal and fecal pH in human health. Front Microbiomes. 2023;2:1192316. https://doi.org/10.3389/frmbi.2023.1192316; Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract—influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol. 2020;11:524. https://doi.org/10.3389/fphar.2020.00524; Fallingborg J, Pedersen P, Jacobsen BA. Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn’s disease. Dig Dis Sci. 1998;43(4):702–5. https://doi.org/10.1023/A:1018893409596; Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–7. https://doi.org/10.1136/gut.48.4.571; Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn’s disease. Am J Gastroenterol. 1997;92(1):114–8. PMID: 8995949; Rane K, Kukreja G, Deshmukh S, Kakad U, Jadhav P, Patole V. Robotic pills as innovative personalized medicine tools: a mini review. Recent Adv Drug Deliv Formul. 2024;18(1):2–11. https://doi.org/10.2174/0126673878265457231205114925; Locatelli I, Kovacic NN, Mrhar A, Bogataj M. Gastric emptying of non-disintegrating solid drug delivery systems in fasted state: relevance to drug dissolution. Expert Opin Drug Deliv. 2010;7(8):967−76. https://doi.org/10.1517/17425247.2010.495982; Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685–93. https://doi.org/10.1124/dmd.108.023630; Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28(1):4–18. https://doi.org/10.2133/dmpk.dmpk-12-rv-099; Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, et al. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol. 2014;61(1):139–47. https://doi.org/10.1016/j.jhep.2014.02.021; Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, et al. Transporter expression in noncancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Drug Metab Dispos. 2018;46(2):189–96. https://doi.org/10.1124/dmd.117.077289; Vildhede A, Kimoto E, Pelis RM, Rodrigues AD, Varma MVS. Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease. Clin Pharmacol Ther. 2020;107(5):1128–37. https://doi.org/10.1002/cpt.1699; Murray M, Zhou F. Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease. Br J Pharmacol 2017;174(13):1908–24. https://doi.org/10.1111/bph.13785; Xu D, You G. Loops and layers of post-translational modifications of drug transporters. Adv Drug Deliv Rev. 2017;116:37–44. https://doi.org/10.1016/j.addr.2016.05.003; Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, et al. Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug–drug interactions. Int J Mol Sci. 2018;19(3):855. https://doi.org/10.3390/ijms19030855; Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, et al. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos. 2009;37(9):1871–7. https://doi.org/10.1124/dmd.109.027367; König J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF. Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011;39(6):1097–102. https://doi.org/10.1124/dmd.110.034991; Hickman D, Pope J, Patil SD, Fakis G, Smelt V, Stanley LA, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998;42(3):402–9. https://doi.org/10.1136/gut.42.3.402; Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 2000;54(1):19–29. https://doi.org/10.1093/toxsci/54.1.19; Deloménie C, Fouix S, Longuemaux S, Brahimi N, Bizet C, Picard B, et al. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001;183(11):3417–27. https://doi.org/10.1128/jb.183.11.3417-3427.2001; Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. https://doi.org/10.1038/ajg.2018.27; Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):1–106. https://doi.org/10.1136/gutjnl-2019-318484; Ford AC, Kane SV, Khan KJ, Achkar J-P, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in Crohn’s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):617–29. https://doi.org/10.1038/ajg.2011.71; Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180; https://www.risksafety.ru/jour/article/view/456
-
2Academic Journal
Authors: Boyko M.S., Osikov M.V., Fedosov A.A., Grekova I.V.
Source: Медицинская иммунология, Vol 25, Iss 3, Pp 655-664 (2023)
Subject Terms: vitamin d3, tnf-α, experimental colitis, vitamin D 3, mpo, MPO, 5-Aminosalicylic acid, disease activity index, 5-aminosalicylic acid, RC581-607, Experimental colitis, витамин D 3, Индекс активности болезни, TNF-α, экспериментальный колит, Immunologic diseases. Allergy, 5-аминосалициловая кислота
-
3Academic Journal
Authors: Fadieienko, G. D., Solomentseva, T. A.
Contributors: Biocodex Ukraine, ООО «Биокодекс Украина», ТОВ «Біокодекс Україна»
Source: Modern Gastroenterology; № 5 (2020); 38—45
Современная гастроэнтерология; № 5 (2020); 38—45
Сучасна гастроентерологія; № 5 (2020); 38—45Subject Terms: воспалительное заболевание кишечника, язвенный колит, приверженность лечению, 5‑аминосалициловая кислота (5‑ASA), месалазин с pH‑зависимым высвобождением, «Aсакол», Eudragit‑S, inflammatory bowel disease, ulcerative colitis, adherence to treatment, 5‑aminosalicylic acid (5‑ASA), pH‑dependent‑release mesalamine, Asacol, EudragitS, запальні захворювання кишечника, виразковий коліт, прихильність до лікування, 5‑аміносаліцилова кислота (5‑ASA), месалазин з pH‑залежним вивільненням, «Асакол», 3. Good health
File Description: application/pdf
Access URL: http://sgastro.com.ua/article/view/MG-2020-5-38
-
4Academic Journal
Authors: Юрий Павлович Успенский, Сергей Витальевич Иванов, Юлия Александровна Фоминых, Андрей Михайлович Сарана, Руслан Орестович Древаль
Source: University Therapeutic Journal, Vol 4, Iss 4 (2022)
Subject Terms: язвенный колит, 5-аминосалициловая кислота, месалазин, Medicine
File Description: electronic resource
-
5Academic Journal
Source: University Therapeutic Journal, Vol 4, Iss 4 (2022)
Subject Terms: Medicine, язвенный колит, месалазин, 5-аминосалициловая кислота
-
6Academic Journal
Source: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Subject Terms: болезнь Крона, диагностика, лечение, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессанты, Medicine
File Description: electronic resource
-
7Academic Journal
Source: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Subject Terms: язвенный колит, диагностика, лечение, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессанты, Medicine
File Description: electronic resource
-
8Academic Journal
Authors: Knyazev O.V., Belousova E.A., Abdulganieva D.I., Gubonina I.V., Kaibullayeva J.A., Marakhouski Y.K., Chashkova E.Y., Shapina M.V., Shchukina O.B., Gegenava B.B., Oliferuk N.S.
Source: Almanac of Clinical Medicine; Vol 49, No 7 (2021); 443-454 ; Альманах клинической медицины; Vol 49, No 7 (2021); 443-454 ; 2587-9294 ; 2072-0505
Subject Terms: inflammatory bowel diseases, Crohn's disease, ulcerative colitis, epidemiology, medical treatment, real world clinical practice, 5-aminosalicylic acid, glucocorticosteroids, immunosuppressants, genetically engineered biological agents, vedolizumab, воспалительные заболевания кишечника, болезнь Крона, язвенный колит, эпидемиология, лекарственная терапия, реальная клиническая практика, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессоры, генно-инженерные биологические препараты, ведолизумаб
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/1619/1399; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2666; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2667; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2668; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2669; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2670; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2671; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2672; https://almclinmed.ru/jour/article/view/1619
-
9Academic Journal
Source: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Subject Terms: иммуносупрессанты, болезнь Крона, диагностика, глюкокортикостероиды, Medicine, лечение, 5-аминосалициловая кислота
-
10Academic Journal
Source: University Therapeutic Journal, Vol 3, Iss 1 (2021)
Subject Terms: иммуносупрессанты, диагностика, глюкокортикостероиды, Medicine, язвенный колит, лечение, 5-аминосалициловая кислота
-
11Academic Journal
Authors: M. V. Shapina, I. L. Khalif, М. В. Шапина, И. Л. Халиф
Source: Meditsinskiy sovet = Medical Council; № 15 (2017); 44-50 ; Медицинский Совет; № 15 (2017); 44-50 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-15
Subject Terms: месалазин, 5-aminosalicylic acid, dosage regimen, mesalazine, 5-аминосалициловая кислота, режим дозирования
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2063/2044; Svartz N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations. Acta Med. Scand., 2009 Apr, 110(6): 577–598.; Peppercorn MA and Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther., 1972 Jun, 181(3): 555–62.; Azad Khan AK, Piris J, and Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (London, England), 1977 Oct, 2(8044): 892–5.; Klotz U, Maier K, Fischer C, and Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N. Engl. J. Med., 1980 Dec, 303(26): 1499–502; van Hees PA, Bakker JH, and van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut, 1980 Jul, 21(7): 632–5.; Schröder H and Campbell DES. Absorption, meta bolism, and excretion of salicylazosulfapyridine in man. Clin. Pharmacol. Ther., 1972 Jul, 13(4): 539–551.; Haagen O Nielsen and Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br. J. Clin. Pharmacol., 1983 Dec, 16(6): 738–40.; Myers B, Evans DN, Rhodes J, Evans BK, Hughes BR, Lee MG, Richens A, and Richards D. Metabo lism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut, 1987 Feb, 28(2): 196–200.; Truelove SC and Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J., 1955 Oct, 2(4947): 1041–8.; Truelove SC and Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br. Med. J., 1959, 1(5119): 387–394.; Misiewica JJ, Lennard-Jones JE, Connell AM. Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis. Lancet, 1965, 1: 185–8.; Sutherland L, May G, and Shaffer E. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med, 1993, 118, 540–9.; Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol., 1982 Apr, 17(3): 389–93.; D’Incà R. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J. Gastroenterol., 2013, 19(34): 5665.; Das KM, Eastwood MA, McManus JPA, and Sircus W. Adverse Reactions during Salicy la-zosulfapyridine Therapy and the Relation with Drug Metabolism and Acetylator Phenotype. N. Engl. J. Med., 1973 Sep, 289(10): 491–495.; Sutherland LR and MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulce rative colitis. In Cochrane Database of Systema tic Reviews. Ed. Chichester, UK: John Wiley & Sons, Ltd, 2006.; Sutherland LR, Roth DE, and Beck PL. Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis. Inflamm. Bowel Dis., 1997, 3(2): 65–78.; Feagan BG and MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. In Cochrane Database of Systematic Reviews. Ed. Chichester, UK: John Wiley & Sons, Ltd, 2012.; Hardy JG, Healey JNC, and Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007 Mar, 1(4): 273–280.; Dew MJ, Harries AD, Evans N, Evans BK, and Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br. Med. J. (Clin. Res. Ed)., 1983, 287(6384): 23–4.; Князев О.В., Беляков Н.И., Каграманова А.В., Фадеева Н.А. Эффективность терапии язвенного колита средней степени тяжести месалазином ММХ. Терапия, 2017, 1(11).; Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, and Flachs H. 5-amino-salicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology, 1982 Nov, 83(5): 1062–70.; Данные инструкции по медицинскому применению препарата Пентаса гранулы, пролонгированного действия для приема внутрь: http://grls.rosminzdrav.ru.; Данные инструкции по медицинскому приме-нению препарата Пентаса таблетки, пролонгированного действия: http://grls.rosminzdrav.ru.; Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, and European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Manage ment of Ulcerative Colitis. Part 2: Current Manage ment. J. Crohns. Colitis, 2017 Jul, 11(7): 769–784.; Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, and Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, 57(7): 893–902.; Maier K, Frühmorgen P, Bode JC, Heller T, von Gaisberg U, and Klotz U. Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid. Dtsch. Med. Wochenschr., 1985 Mar, 110(10): 363–8.; Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, and Müller M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther., 2003 Feb, 17(3): 395–402.; Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1(59).; Данные инструкции по медицинскому применению препарата Мезавант таблетки пролонгированного действия, покрытые кишечнорастворимой оболочкой: http://grls.rosminzdrav.ru.; Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Grein wald R, and Mueller R. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, rando mised, non-inferiority trial. Gut, 2009, 58(2): 233–240.; Flouri B, Hagge H, Tucat G, Maetz D, Hbuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee, O Dewit AAM, Probert CS, and Aoucheta D. Randomised clinical trial: Once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment. Pharmacol. Ther., 2013, 37(8): 767–775.; Kane S, Huo D, and Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin. Gastroenterol. Hepatol., 2003 May, 1(3): 170–3.; Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, and Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroentero-logy, 2010 Apr, 138(4): 1286–96, 1296–3.; D’Haens G, Sandborn WJ, Barrett K, Hodgson I, and Streck P. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am. J. Gastroenterol., 2012 Jul, 107(7): 1064–77.; Kane S, Holderman W, Jacques P, and Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. Patient Prefer. Adherence, 2008 Feb, 2: 253–8.; Bokemeyer B, Hommes D, Gill I, Broberg P, and Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J. Crohns. Colitis, 2012 May, 6(4): 476–82.; Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, Savarino V, Sturniolo GC, Vecchi M, Ardia A, and Bellinvia S. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX® with Asacol®. Aliment. Pharmacol. Ther., 2009 Nov, 30(9): 908–918.; Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, and Probert CSJ. One-year investigator-blind rand-omized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm. Bowel Dis., 2012 Oct, 18(10): 1885–93.; Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horyn ski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Grein wald R, and Mueller R. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative co li-tis. Aliment. Pharmacol. Ther., 2011 Feb, 33(3): 313–322.; Watanabe M, Hanai H, Nishino H, Yokoyama T, Terada T, and Suzuki Y. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study. Inflamm. Bowel Dis., 2013 Jul, 19(8): 1681–90.; Kane SV, Cohen RD, Aikens JE, and Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am.; J. Gastroenterol., 2001 Oct, 96(10): 2929–33.; Ediger JP, Walker JR, Graff L, Lix L, Clara I, Raw-sthorne P, Rogala L, Miller N, McPhail C, Deering K, and Bernstein CN. Predictors of medication adherence in inflammatory bowel disease. Am. J. Gastroenterol., 2007 Jul, 102(7): 1417–26.; Loftus EV. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm. Bowel Dis., 2006 Dec, 12(12): 1107–13.; Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2, 2013.; Lachaine J. et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterology. 2013. 13.
-
12Academic Journal
Authors: I. G. Bakulin, M. I. Skalinskaya, E. V. Skazyvaeva, И. Г. Бакулин, М. И. Скалинская, Е. В. Сказываева
Source: Meditsinskiy sovet = Medical Council; № 15 (2017); 76-80 ; Медицинский Совет; № 15 (2017); 76-80 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-15
Subject Terms: противорецидивная терапия, Mesalazine, 5-aminosalycil acid, remission induction, anti-recurrence therapy, месалазин, 5-аминосалициловая кислота, индукция ремиссии
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2068/2049; Бакулин И.Г., Станке Д.А., Белоусова Е.А. и др. Индексы активности - объективные критерии оценки степени тяжести язвенного колита. Экспериментальная и клиническая гастроэнтерология, 2008, 6: 14-16.; Бакулин И.Г., Станке Д.А. Современные представления о течении и консервативных методах лечения неспецифического язвенного колита. Военно-медицинский журнал, 2008, 329(11): 50-56.; Sutherland L, Roth D, Beck P et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2002, 4: CD000544.; Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-amino-salicylic acid is dependent on peroxisome pro-liferator-activated receptor-gamma. J Exp Med, 2005, 201: 1205–1215.; Santucci L, Wallace J, Mencarelli A et al. Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxide-releasing derivative of mesalamine in rodent colitis. Gastroenterology, 2005, 128: 1243–1257.; Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2012, 10: CD000544.; Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2012, 10: CD000543.; Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017, 1(59): 6–30.; Probert CS, Dignass AU, Lindgren S. et al. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis, 2014 Mar, 8(3): 200-7.; Lakatos PL. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun. World J Gastroenterol, 2009, 15: 1799– 1804.; Nardelli S, Pisani LF, Tontini GE et al. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol, 2017 Jul, 10(7): 545-552.; Brereton N, Bodger K, Kamm MA, et al. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ, 2010, 13: 148–161.; Sandborn WJ, Kamm MA, Lichtenstein GR. SPD476, a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naïve: an analysis of pooled data from two phase III studies. Gastroenterology, 2007, 130: A–482.; Demyanova E, Vakhitov T, Sitkin S. Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changes. J Crohns Colitis, 2017, 11(Suppl 1): S406. doi:10.1093/ecco-jcc/jjx002.762.; Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci, 1995, 40: 296–304.; Круис В., Ситкин С.И. Заживление слизистой оболочки при воспалительных заболеваниях кишечника: Влияние месалазина и различных механизмов его действия на заживление слизистой оболочки кишечника при язвенном колите. М.: Форте принт, 2013. 36 с.; Ito H, Iida M, Matsumoto T, Suzuki Y. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis, 2010, 16: 1567–1574.; Gibson PR, Fixa B, Pekárková B, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther, 2006, 23: 1017–1026.; Prantera C, Kohn A, Campieri M, Caprilli R, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther, 2009, 30: 908–918.; Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf, 2007, 6: 99–107.; Ford AC, Khan KJ, Sandborn WJ et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol., 2011, 106: 2070–2077.; Prasher H, Savania P, Jazrawi R. Changing patients with ulcerative colitis to once daily mesalazine improves outcome and reduces cost in primary and secondary care. J Crohns Colitis, 2013, 7: 239–240.; Motoya S, Tanaka H, Miyakawa M. et al. Efficacy of switching to pH-dependent release formulation of mesalazine at 3.6 g/day from time-dependent release formulation of mesalazine at 4.0 g/day in patients with Ulcerative Colitis. J Crohns Colitis, 2015, 9(suppl 1): S319–S320.; Robinson A, Hankins M, Wiseman G et al. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther., 2013, 38: 531–538.; Acosta MB, Vallejo N, Iglesia D et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (mayo score 0 vs 1): a longitudinal cohort study. J Crohns Colitis, 2016, 10: 13–19.; Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2016 May 9, 5: CD000544.; Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, et al. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intest Res, 2017 Jul, 15(3): 368–379.; D’Haens GR, Sandborn WJ, Zou G, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther, 2017 Aug, 46(3): 292-302.; Flourie B, Hagege H, Tucat GD et.al. Rando mi sed clinical trial: once-vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther, 2013, 37: 767-775.; Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. Inflamm. Bowel Dis, 2017 May, 23(5): 822–832.; Masakazu Nagahori, Shuji Kochi, Hiroyuki Hanai, Takayuki Yamamoto, Shiro Nakamura, Soji Omuro, Mamoru Watanabe, Toshifumi Hibi, and OPTIMUM Study Group. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol, 2017, 17(1): 47.; Ситкин С.И., Жигалова Т.Н., Коновалова Н.О., Ткаченко Е.И. Возможности повышения эффективности терапии при язвенном колите. Врач, 2011, 10: 42–46.; Бакулин И.Г., Новоженов В.Г., Станке Д.А. Динамика клинико-эндоскопических показателей активности заболевания у пациентов с обострением язвенного колита на фоне монотерапии месалазином. Военно-медицинский журнал, 2007, 328(3): 77-78.
-
13Academic Journal
Authors: Гармонов, С., Нгуен, З., Мингазетдинов, И., Юсупова, Л., Шитова, Н., Исмаилова, Р., Сопин, В.
Subject Terms: 5-АМИНОСАЛИЦИЛОВАЯ КИСЛОТА, МОЧА, СПЕКТРОФОТОМЕТРИЯ
File Description: text/html
-
14Academic Journal
Source: Вестник Казанского технологического университета.
Subject Terms: 5-АМИНОСАЛИЦИЛОВАЯ КИСЛОТА, МОЧА, СПЕКТРОФОТОМЕТРИЯ
File Description: text/html
-
15Academic Journal
Authors: Палковский, О. Л.
Subject Terms: лекарственные средства, сравнительная характеристика, 5-аминосалициловая кислота
Relation: Палковский, О. Л. Сравнительная характеристика лекарственных средств 5-аминосалициловой кислоты (обзор литературы) [Электронный ресурс] / О. Л. Палковский // Актуальные проблемы медицины Гомельской области : материалы обл. науч.-практ. конф., посвящ. 75-летию учреждения «Гомельская областная клиническая больница», Гомель, 24 окт. 2019 г. / Упр. здравоохранения Гомел. исполкома, Гомел. обл. клин. больница, Гомел. гос. мед. ун-т; редкол. : В. А. Бугаков [и др.]. – Гомель : ГомГМУ, 2019. – С. 109-110. – 1 электрон. опт. диск (CD-ROM).; https://elib.gsmu.by/handle/GomSMU/6308
Availability: https://elib.gsmu.by/handle/GomSMU/6308
-
16Academic Journal
Source: Дальневосточный медицинский журнал.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, БОЛЕЗНЬ КРОНА (БК), ДАЛАРГИН, ОКСИДАТИВНЫЙ СТАТУС, ПРОЛИФЕРАТИВНАЯ АКТИВНОСТЬ ЭПИТЕЛИЯ, ХЕМИЛЮМИНЕСЦЕНЦИЯ, 5-АМИНОСАЛИЦИЛОВАЯ КИСЛОТА, КАЧЕСТВО ЖИЗНИ, CROHN'S DISEASE, CHEMILUMINESCENCE'S, 3. Good health
File Description: text/html
-
17Academic Journal
Authors: Осиков М.В., Кайгородцева Н.В., Бойко М.С., Федосов А.А.
Source: Российский иммунологический журнал
Subject Terms: Experimental colitis, ozone, 5-Aminosalicylic acid, neutrophils, экспериментальный колит, озон, 5-аминосалициловая кислота, нейтрофилы, Il-17
Availability: https://repository.rudn.ru/records/article/record/96826/
-
18Academic Journal
Authors: Boyko M.S., Osikov M.V., Fedosov A.A., Grekova I.V.
Source: Медицинская иммунология
Subject Terms: Experimental colitis, vitamin D 3, disease activity index, MPO, TNF-α, 5-Aminosalicylic acid, экспериментальный колит, витамин D 3, Индекс активности болезни, 5-аминосалициловая кислота
Availability: https://repository.rudn.ru/records/article/record/107143/
